NASDAQ:ALPN
Alpine Immune Sciences Inc Stock News
$64.56
-0.0600 (-0.0929%)
At Close: Apr 26, 2024
The Peck Company Holdings Expands into Rhode Island with $7.256 Million EPC Contract for a 5.3MW Solar Project
12:00am, Wednesday, 07'th Oct 2020
The Peck Company Holdings, Inc. (NASDAQ: PECK) (the “Company” or “Peck”), a leading commercial solar engineering, procurement and construction (EPC) c
Alpine Immune Sciences (ALPN) Investor Presentation - Slideshow
06:03pm, Thursday, 13'th Aug 2020
The following slide deck was published by Alpine Immune Sciences, Inc. in conjunction with this event..
Alpine Immune Sciences Reports Second Quarter 2020 Financial Results and Provides Corporate Update
08:05pm, Tuesday, 11'th Aug 2020
Alpine Immune Sciences Reports Second Quarter 2020 Financial Results and Provides Corporate Update
Alpine Immune Sciences Reports Second Quarter 2020 Financial Results and Provides Corporate Update
12:00am, Tuesday, 11'th Aug 2020
Alpine Immune Sciences Reports Second Quarter 2020 Financial Results and Provides Corporate Update
Alpine Immune Sciences to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference
08:05pm, Wednesday, 05'th Aug 2020
Alpine Immune Sciences to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference
Alpine Immune Sciences to Report Second Quarter 2020 Financial Results and Provide Corporate Update
08:05pm, Tuesday, 04'th Aug 2020
Alpine Immune Sciences to Report Second Quarter 2020 Financial Results and Provide Corporate Update
Alpine Immune Sciences to Report Second Quarter 2020 Financial Results and Provide Corporate Update
12:00am, Tuesday, 04'th Aug 2020
Alpine Immune Sciences to Report Second Quarter 2020 Financial Results and Provide Corporate Update
Alpine Immune Sciences Announces $60 Million Private Placement
01:15pm, Friday, 24'th Jul 2020
Alpine Immune Sciences Announces $60 Million Private Placement
Did Business Growth Power Alpine Immune Sciences' (NASDAQ:ALPN) Share Price Gain of 126%?
10:45am, Wednesday, 22'nd Jul 2020
Alpine Immune Sciences, Inc. (NASDAQ:ALPN) shareholders have seen the share price descend 13% over the month. But that...
The Zacks Analyst Blog Highlights: Alpine Immune Sciences, Actinium Pharmaceuticals, Pacira BioSciences and Translate Bio
01:05pm, Wednesday, 08'th Jul 2020
The Zacks Analyst Blog Highlights: Alpine Immune Sciences, Actinium Pharmaceuticals, Pacira BioSciences and Translate Bio
Alpine Immune Sciences, Inc. (ALPN) Shares March Higher, Can It Continue?
11:35am, Wednesday, 08'th Jul 2020
As of late, it has definitely been a great time to be an investor in Alpine Immune Sciences, Inc. (ALPN).
Alpine Begins Dosing in Phase I Study for Advanced Malignancies
04:09pm, Thursday, 25'th Jun 2020
Alpine (ALPN) doses the first patient in the phase I NEON-1 study evaluating its pipeline candidate ALPN-202 for treating patients with advanced malignancies.
Alpine Immune Sciences Announces First Patient Dosed in NEON-1 Phase 1 Trial of ALPN-202 in Patients with Advanced Malignancies
12:00pm, Wednesday, 24'th Jun 2020
Alpine Immune Sciences Announces First Patient Dosed in NEON-1 Phase 1 Trial of ALPN-202 in Patients with Advanced Malignancies
Alpine Immune Sciences Announces First Patient Dosed in NEON-1 Phase 1 Trial of ALPN-202 in Patients with Advanced Malignancies
12:00am, Wednesday, 24'th Jun 2020
Alpine Immune Sciences Announces First Patient Dosed in NEON-1 Phase 1 Trial of ALPN-202 in Patients with Advanced Malignancies
